Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Empiric Anti-Thymocyte Globulin (ATG) Dosing in Ex-Vivo CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) May Result in ATG Overexposure That Negatively Affects Outcomes
ÌÇÐÄ´«Ã½
Empiric Anti-Thymocyte Globulin (ATG) Dosing in <i>Ex</i>-<i>Vivo</i> CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) May Result in ATG Overexposure That Negatively Affects Outcomes Scordo, M., Bhatt, V., Smith, M., Thoren, K., Hilden, P., Cho, C., Shah, G. L., Maloy, M., Papadopoulos, E. B., Jakubowski, A. A., O'Reilly, R. J., Castro-Malaspina, H., Tamari, R., Shafer, B. C., Perales, M., Giralt, S. A. ELSEVIER SCIENCE INC. 2018: S71-S72View details for